For now, the current study shows that a significant
population of lung cancer patients with HER2 mutations exists.
Not exact matches
Key findings in this study show that 5 - year survival for older
lung cancer surgery
patients is favorable; surgeons will be able to better individualize care for older
lung cancer patients based on newly and uniquely linked data, and the prevalence
of lung cancer is expected to increase as the
population continues to age.
«This greater than expected survival in older
patients selected for operative therapy is noteworthy,» said Dr. Fernandez, «especially considering that the prevalence
of lung cancer is expected to increase as the
population continues to grow older and more people survive into old age.»
Commenting on the findings, Prof Robert Pirker, programme director for
lung cancer at the Vienna General Hospital in Vienna, Austria, not involved in the study, said: «This subgroup analysis shows that the effect
of necitumumab was slightly greater in
patients with EGFR expressing tumours than it was in the entire SQUIRE
population.
«As the
population of the United States ages, there will be a higher number
of lung cancer patients with comorbidities at diagnosis.»
By identifying a significant
population of HER2 +
lung cancer patients, the current study demonstrates the need for these therapies.
Assuming that the findings
of the review reflected a causal relation between smoking cessation and risk
of all cause mortality, we further investigated the data by constructing life tables for a hypothetical group
of 100
patients aged 65 years with early stage
lung cancer to estimate how many deaths would be prevented by smoking cessation within the non-small cell
lung cancer and small cell
lung cancer populations during five years.